Allergy Therapeutics (AGY)
10/01/2018 - 15:19 RNS
RNS Number: 5221B Allergy Therapeutics PLC 10 January 2018 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Allergy The...
09/01/2018 - 07:23 StockMarketWire
Allergy Therapeutics said recruitment of the group's phase III clinical trial with PQ Birch (PQBirch301) has been completed...
09/01/2018 - 07:00 RNS
RNS Number: 2889B Allergy Therapeutics PLC 09 January 2018 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") PQ Birch Phase III clinical trial completes recruitment 9 January 2018 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announces that recruitment of the Gro...
12/12/2017 - 07:49 StockMarketWire
Allergy Therapeutics has entered into a co-development collaboration agreement with Ergomed for the clinical developme...
No news for Allergy Therapeutics during this period.
Join interactive investor
- £22.50 fixed quarterly charge includes £22.50 in trading credits
- £10 per trade or £6 for frequent traders
- No % platform fees
- £1 per trade for regular investment or dividend reinvestment